uracil has been researched along with Kidney Failure, Chronic in 13 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5%) patients (calcium channel blockers, ACE inhibitors, statins, diuretics, tacrolimus); four patients required further adjustment of antihypertensive drugs or tacrolimus dosage on-treatment." | 5.48 | Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort. ( Chmelova, K; Frankova, S; Kreidlova, M; Merta, D; Senkerikova, R; Sperl, J, 2018) |
| " In the double-blind phase, the incidence of treatment-emergent adverse events (TEAEs) was 72." | 2.94 | Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study. ( Achira, M; Ishida, K; Kaku, K; Shimizu, K; Umeda, Y, 2020) |
| "However, the best strategy to identify DPD deficiency in End Stage Renal Disease (ESRD) patients is unknown." | 1.62 | Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results. ( Gaible, C; Loriot, MA; Narjoz, C; Pallet, N; Roueff, S, 2021) |
| "5%) patients (calcium channel blockers, ACE inhibitors, statins, diuretics, tacrolimus); four patients required further adjustment of antihypertensive drugs or tacrolimus dosage on-treatment." | 1.48 | Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort. ( Chmelova, K; Frankova, S; Kreidlova, M; Merta, D; Senkerikova, R; Sperl, J, 2018) |
| "New highly effective treatments for chronic hepatitis C virus (HCV) infection are now available, but safety and efficacy data on the use of anti-HCV therapies in patients with renal failure, particularly those requiring PD, remain limited." | 1.46 | Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis. ( Cole, J; Stark, JE, 2017) |
| "A 61-year-old man on hemodialysis due to chronic renal failure caused by diabetes mellitus was diagnosed as having ascending colon cancer with multiple liver metastases." | 1.38 | [A case of stage IV colon cancer effectively treated with tegafur uracil/calcium folinate in a patient on hemodialysis]. ( Kobayashi, M; Maeda, H; Okamoto, K; Takeshita, A, 2012) |
| "In a rat model of chronic renal failure, 5/6-nephrectomized [5/6N] rats were treated orally with DPP-4 inhibitors (linagliptin, sitagliptin, alogliptin) or placebo once daily for 4 days from 8 weeks after surgery, to identify the most appropriate treatment for cardiac dysfunction associated with CKD." | 1.37 | Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. ( Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Gaible, C | 1 |
| Narjoz, C | 1 |
| Loriot, MA | 1 |
| Roueff, S | 1 |
| Pallet, N | 1 |
| Tatar, B | 1 |
| Köse, Ş | 1 |
| Ergun, NC | 1 |
| Turken, M | 1 |
| Onlen, Y | 1 |
| Yılmaz, Y | 1 |
| Akhan, S | 1 |
| Stark, JE | 1 |
| Cole, J | 1 |
| Sperl, J | 1 |
| Kreidlova, M | 1 |
| Merta, D | 1 |
| Chmelova, K | 1 |
| Senkerikova, R | 1 |
| Frankova, S | 1 |
| Yaraş, S | 1 |
| Üçbilek, E | 1 |
| Özdoğan, O | 1 |
| Ateş, F | 1 |
| Altıntaş, E | 1 |
| Sezgin, O | 1 |
| Özer Etik, D | 1 |
| Suna, N | 1 |
| Öcal, S | 1 |
| Selçuk, H | 1 |
| Dağlı, Ü | 1 |
| Çolak, T | 1 |
| Hilmioğlu, F | 1 |
| Boyacıoğlu, AS | 1 |
| Haberal, M | 1 |
| Kaku, K | 1 |
| Ishida, K | 1 |
| Shimizu, K | 1 |
| Achira, M | 1 |
| Umeda, Y | 1 |
| Pockros, PJ | 1 |
| Reddy, KR | 1 |
| Mantry, PS | 1 |
| Cohen, E | 1 |
| Bennett, M | 1 |
| Sulkowski, MS | 1 |
| Bernstein, DE | 1 |
| Cohen, DE | 1 |
| Shulman, NS | 1 |
| Wang, D | 1 |
| Khatri, A | 1 |
| Abunimeh, M | 1 |
| Podsadecki, T | 1 |
| Lawitz, E | 1 |
| Ponziani, FR | 1 |
| Siciliano, M | 1 |
| Lionetti, R | 1 |
| Pasquazzi, C | 1 |
| Gianserra, L | 1 |
| D'Offizi, G | 1 |
| Gasbarrini, A | 1 |
| Pompili, M | 1 |
| Chaykovska, L | 1 |
| von Websky, K | 1 |
| Rahnenführer, J | 1 |
| Alter, M | 1 |
| Heiden, S | 1 |
| Fuchs, H | 1 |
| Runge, F | 1 |
| Klein, T | 1 |
| Hocher, B | 1 |
| Okamoto, K | 1 |
| Kobayashi, M | 1 |
| Maeda, H | 1 |
| Takeshita, A | 1 |
| Sakamoto, K | 1 |
| Arita, S | 1 |
| Hisikawa, E | 1 |
| Yaguchi, H | 1 |
| Arima, H | 1 |
| Matsumoto, M | 1 |
| Hachisu, T | 1 |
| Kashiwabara, H | 1 |
| Yokoyama, T | 1 |
| Yanagisawa, T | 1 |
| Arimoto, T | 1 |
| Kishimoto, H | 1 |
| Takahashi, Y | 1 |
| Urade, M | 1 |
| Yoshioka, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal[NCT02207088] | Phase 3 | 68 participants (Actual) | Interventional | 2014-09-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after < LLOQ during treatment, confirmed increase of > 1 log (subscript)10(subscript) IU/mL above the lowest value post-baseline HCV RNA during treatment, or HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks of treatment. (NCT02207088)
Timeframe: Up to 24 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA ± RBV | 0 |
Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants completing treatment and with HCV RNA < LLOQ at the end of treatment. (NCT02207088)
Timeframe: Within 12 weeks after the last dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA ± RBV | 1.5 |
SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | percentage of participants (Number) |
|---|---|
| 3-DAA ± RBV | 94.1 |
3 trials available for uracil and Kidney Failure, Chronic
| Article | Year |
|---|---|
Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study.
Topics: Aged; Asian People; Diabetes Mellitus, Type 2; Diet Therapy; Dipeptidyl-Peptidase IV Inhibitors; Dou | 2020 |
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dose-Response Relation | 2016 |
[Pharmacokinetic study of UFT in cancer patients receiving maintenance dialysis].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1995 |
10 other studies available for uracil and Kidney Failure, Chronic
| Article | Year |
|---|---|
Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results.
Topics: Case-Control Studies; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP) | 2021 |
Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, C | 2019 |
Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Sc | 2017 |
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.
Topics: 2-Naphthylamine; Anilides; Antihypertensive Agents; Antiviral Agents; Carbamates; Cyclopropanes; Dru | 2018 |
Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, C | 2019 |
Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactio | 2019 |
Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; H | 2017 |
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Topics: Animals; Area Under Curve; Cardiomyopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibit | 2011 |
[A case of stage IV colon cancer effectively treated with tegafur uracil/calcium folinate in a patient on hemodialysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms; Combined Modality Ther | 2012 |
[Dynamic change of serum UFT concentration in a patient with tongue cancer complicating chronic renal failure].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 1995 |